Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial

Moreno, Lucas; Weston, Rebekah; Owens, Cormac; Valteau-Couanet, Dominique; Gambart, Marion; Castel, Victoria; Zwaan, C. Michel; Nysom, Karsten; Gerber, Nicolas; Castellano, Aurora; Laureys, Genevieve; Ladenstein, Ruth; Rössler, Jochen; Makin, Guy; Murphy, Dermot; Morland, Bruce; Vaidya, Sucheta; Thebaud, Estelle; van Eijkelenburg, Natasha; Tweddle, Deborah A.

doi:10.1200/jco.23.00458

Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial

Moreno, Lucas

;

Weston, Rebekah

;

Owens, Cormac

;

Valteau-Couanet, Dominique

;

Wheatley, Keith

;et.al.

(2024) Journal of Clinical Oncology — Vol. 42, n° 10, p. 1135-1145 (2024)

Files

BevacizumabIrinotecanorTopotecanAddedtoTemozolomideforChildrenWithRelapsedandRefractoryNeuroblastoma.pdf

Open Access
Adobe PDF
1.17 MB

Download

Details

Authors

Moreno, Lucas
Author
Weston, Rebekah
Author
Owens, Cormac
Author
Valteau-Couanet, Dominique
Author
Brichard, BenedicteUCLouvain
Author
Wheatley, Keith
Author
et. al.

Abstract

Outcomes for children with relapsed and refractory high-risk neuroblastoma (RR-HRNB) remain dismal. The BEACON Neuroblastoma trial (EudraCT 2012-000072-42) evaluated three backbone chemotherapy regimens and the addition of the antiangiogenic agent bevacizumab (B).

Affiliations

UCLouvainSSH/IACS - Institute of Analysis of Change in Contemporary and Historical Societies

Citations

APA
Chicago
FWB

Moreno, L., Weston, R., Owens, C., Valteau-Couanet, D., Gambart, M., Castel, V., Zwaan, C. M., Nysom, K., Gerber, N., Castellano, A., Laureys, G., Ladenstein, R., Rössler, J., Makin, G., Murphy, D., Morland, B., Vaidya, S., Thebaud, E., van Eijkelenburg, N., et al. (2024). Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial. Journal of Clinical Oncology, 42(10), 1135-1145. https://doi.org/10.1200/jco.23.00458 (Original work published 2024)